NCT04397965Unknown不适用
Cascade CGM 15-Day US Performance Assessment
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 10
- 主要终点
- Feasibility of Use
研究概览
简要总结
To assess a 15-day wear period of the Cascade Continuous Glucose Monitoring (CGM) System
详细描述
To assess a 15-day wear period for the Cascade CGM. The study wear period includes four in-clinic days in which frequent blood draws and Yellow Springs Instrument (YSI) glucose measurements will be performed. Participants will be blinded to CGM glucose values during the study. A retrospective performance assessment will be conducted following the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least 6 months
- •18 years of age or older
- •Currently self-monitoring capillary blood glucose (on average at least three times per day or more) or using a CGM for at least three months -Willing to follow all study procedures, including attending all clinic visits (including in- clinic sessions during which a venous line will be inserted for blood sampling), wearing a CGM sensor(s) for fifteen days, performing fingertip glucose tests for self-monitoring, and keeping a diary of activities.
- •Be willing to wear 2 investigational CGM devices.
排除标准
- •Known allergy to medical grade adhesives
- •Magnetic Resonance Imaging (MRI) scheduled during fifteen-day CGM sensor wear period
- •Persons with type 2 diabetes using diet and exercise only for diabetes management
- •Used an investigational drug within 30 days prior to study entry
- •Hematocrit < 35% for females and <40% for males (obtained during screening)
- •Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
- •Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g., percutaneous transluminal coronary angioplasty (PTCA), stent placement), or coronary artery bypass graft (CABG) within the past six months
- •Diagnosis of the following diabetic autonomic neuropathies: orthostatic hypotension, heart rate anomalies, gastroparesis
- •Cerebrovascular incident within the past six months
- •History or presence of eczema, psoriasis, atopic or contact dermatitis
- •Subject must not be pregnant at the start of the study.
- •Current use or within one-week exposure to topical medications at the proposed insertion sites
- •Seizure disorder (epilepsy)
- •Malignancy within the past five years, except basal cell or squamous cell skin cancers
- •Major surgical operation within 30 days prior to screening
- •Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity (reason for exclusion will be clearly documented by investigator or designee)
- •Subject has experienced severe hypoglycemia or severe hyperglycemia in the last six months. Severe hypoglycemia is defined as having low blood glucose levels that requires assistance from another person to treat. Severe hypoglycemia is classed as a diabetic emergency. Severe hyperglycemia is defined as a blood ketone level >1.6 millimolar (mM).
结局指标
主要结局
Feasibility of Use
时间窗: 15 days
Validate the feasibility of a 15-day wear period of the Cascade CGM. The primary endpoint is an 80% sensor survival rate over a 15-day wear period, which includes four in-clinic days and eleven at-home days.
次要结局
- Performance(15 days)
研究者
相似试验
已完成
不适用
Cascade CGM 15-day Performance AssessmentContinuous Glucose MonitoringNCT04099043WaveForm Technologies Inc.10
已完成
不适用
tility of continuous glucose monitoring (CGMS) in children with type I diabetes on intensive treatment regimensNutritional, Metabolic, EndocrineDiabetesISRCTN28387915Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead35
已完成
不适用
Periodic Use of Continuous Glucose Monitoring With Personalized Diet Interventions Using AI Camera Among Non-insulin Treated Type 2 DiabetesType 2 DiabetesNCT06594055Kangbuk Samsung Hospital120
已完成
不适用
Glucomen Day Cascade CGM System 21-Day Wear StudyEfficacy of a 21-Day Wear Period for the Cascade CGMNCT05460260WaveForm Technologies Inc.10
已完成
不适用
Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix DefinitionDiabetic Blood Glucose MonitoringDiabetes Mellitus, Type 2NCT01390610HealthPartners Institute27